Descripción

Statistical comparison of clinical endpoints or biomarkers between GTB1 and placebo groups in the IBS-D trial. The analysis evaluates whether the probiotic intervention is associated with measurable improvements in gastrointestinal parameters.

Figure 16

Chart

Source Paper

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.

Nutrients (2022)

PMID: 35631156

DOI: 10.3390/nu14102015

Cite This Figure

![Figure 16: Statistical comparison of clinical endpoints or biomarkers between GTB1 and placebo groups in the IBS-D trial. The analysis evaluates whether the probiotic intervention is associated with measurable improvements in gastrointestinal parameters.]()

> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)

<figure>
  <img src="" alt="Statistical comparison of clinical endpoints or biomarkers between GTB1 and placebo groups in the IBS-D trial. The analysis evaluates whether the probiotic intervention is associated with measurable improvements in gastrointestinal parameters." />
  <figcaption>Figure 16. Statistical comparison of clinical endpoints or biomarkers between GTB1 and placebo groups in the IBS-D trial. The analysis evaluates whether the probiotic intervention is associated with measurable improvements in gastrointestinal parameters.<br>  Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption>
</figure>

Evidencia relacionada

Lactobacillus plantarum para Irritable Bowel Syndrome (IBS)

Calificación B · 5 estudios